Academic Journal
Reinfection and Resistance Associated Substitutions Following a Minimal Monitoring Approach for HCV Treatment in MINMON Trial
| العنوان: | Reinfection and Resistance Associated Substitutions Following a Minimal Monitoring Approach for HCV Treatment in MINMON Trial |
|---|---|
| المؤلفون: | Han, Win Min, Solomon, Sunil Suhas, Smeaton, Laura, Avihingsanon, Anchalee, Wagner Cardoso, Sandra, Li, Jiani, Parvangada, Aiyappa, Sulkowski, Mark, Naggie, Susanna, Martin, Ross, Mo, Hongmei, Maiorova, Evguenia, Wyles, David |
| المساهمون: | National Institute of Allergy and Infectious Diseases, National Institutes of Health |
| المصدر: | Clinical Infectious Diseases ; ISSN 1058-4838 1537-6591 |
| بيانات النشر: | Oxford University Press (OUP) |
| سنة النشر: | 2024 |
| الوصف: | Background Simplified approaches to hepatitis C virus (HCV) treatment delivery are needed to meet elimination goals. However, the impact of low-touch strategies on individuals at higher risk due to treatment failure or reinfection is unknown. We estimated HCV reinfection rates, and the impact of resistance associated substitutions (RASs) on response in the ACTG A5360 (MINMON) trial. Methods HCV RNA evaluations were scheduled at weeks 0, 24 (sustained viral response [SVR] visit), 48, and 72. Participants with post-entry HCV RNA ≥ lower limit of quantification (LLoQ) had deep sequencing of NS5A and NS5B genes performed. Phylogenetic analysis distinguished between reinfection and treatment failure. Reinfection rates per 100 person-years (PYS) were calculated with 95% confidence interval (CI) constructed using Poisson distribution. Results Of 397 participants with post-entry HCV RNA, 29 had ≥LLoQ and available sequencing data. Of those 29, 5 participants initially designated as non-SVR, and 12 participants initially attaining SVR (evaluated at week 24) were determined to have reinfections (total 17 reinfections) (reinfection rate 3.9/100 PYS [95% CI, 2.4–6.2]). All 17 participants with HCV reinfection were male (13 MSM and 15 with HIV). Of 29 had ≥LLoQ, 12 were identified as treatment failure. SVR (excluding reinfections) in presence and absence of baseline RAS was 93.5% (43/46) and 97% (337/346), respectively, with an overall SVR rate of 97.0% [95% CI, 94.8–98.3] (385/397). Conclusions Accounting for reinfections, SVR in MINMON was 97.0% further supporting simplified HCV treatment. No significant difference in SVR was found by baseline velpatasvir RAS. The high reinfection rate, especially among men who have sex with men (MSM) with human immunodeficiency virus (HIV), underscores the need to scale-up evidence-based interventions to reduce reinfection. Clinical Trials Registration NCT03512210 |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1093/cid/ciae627 |
| DOI: | 10.1093/cid/ciae627/61242161/ciae627.pdf |
| الاتاحة: | https://doi.org/10.1093/cid/ciae627 https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciae627/61242161/ciae627.pdf |
| Rights: | https://academic.oup.com/pages/standard-publication-reuse-rights |
| رقم الانضمام: | edsbas.76046827 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/cid/ciae627 |
|---|